Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
Patent application covers key technology innovations for delivering therapeutic agents Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy Allowance provides broad IP protection for...
SPZI: JP 3E Holdings, Inc. Accelerates Growth with Major Corporate Milestones Toward Uplisting
NEW YORK, October 14, 2024 – PRISM MediaWire - JP 3E Holdings, Inc. (OTC: SPZI), formerly Spooz, Inc., is excited to announce a series of significant corporate developments that mark a new era of growth and expansion for the company. These strategic initiatives...
In Light of World Mental Health Day, PRISM Highlights Mental Health Index Companies Making a Difference
New York, New York, October 10, 2024 - PRISM MediaWire - PRISM MediaWire - Mental health has not always been a topic to discuss as easily as other health related topics due to the stigma surrounding it. Those who have identified having a mental health condition...
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
PITTSBURGH, Oct. 09, 2024 - PRISM MediaWire - Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan...
SKYX Provides Corporate Update, including Significant Insider Buying
MIAMI, Oct. 09, 2024 - PRISM MediaWire - SKYX (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive smart platform technology company with over 97 issued and pending patents in the U.S. and globally, and which owns over 60 lighting and home décor websites...
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics...
Sono-Tek Announces Fiscal Second Quarter and First Half 2025 Earnings Conference Call
Conference Call on Tuesday, October 15, 2024 at 10:00 am ET MILTON, NY, October 8, 2024 – PRISM MediaWire - Sono-Tek Corporation (NASDAQ: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that the Company will hold a...
SKYX Secures $11 Million Strategic Investment at $2.00 Per Share, Preferred Stock Convertible, Led by Global Marriott Hotel-Chain Developer, Lance Shaner, Owner of over 60 Hotels, Primarily Marriotts
Management Emphasizes That It Has Sufficient Cash to Achieve Its Goals Including Recently Announced Collaborations and Being Cash Flow Positive During 2025 The $11 Million Investment includes Leading Builders and Hotel Developers MIAMI, October 07, 2024 - PRISM...
AmpliTech Group Announces Receipt of Notice of Allowance for Patents in 5G and Cryogenic Technology For Quantum Computing Applications
Hauppauge, NY, October 7, 2024 – PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including...
Entrevista exclusiva com Newton Santana, Presidente e Diretor da BEVAP Bioenergia, em antecipação ao Biocombustíveis Brasil 2024
London, October 5, 2024 - PRISM MediaWire - Temos o prazer de compartilhar uma entrevista exclusiva com Newton Santana, Presidente e Diretor da BEVAP Bioenergia, em antecipação ao Biocombustíveis Brasil 2024 que acontecerá nos dias 27 e 28 de novembro em São Paulo....